UNSPSC 51282956: Ofloxacin

This classification denotes a quinolone antibiotic with the molecular formula C18H20FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) A4P49JAZ9H, chemically known as 86393-32-0 (hydrochloride, monohydrate) but more generally known as ofloxacin, which bears U.S. National Institutes of Health Compound Identifier 2764. European Medicines Agency schedules Ofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09422MIG.

UNSPSC 51282956 Ofloxacin is a Commodity code representing pharmaceutical products, but recent state and local solicitations tagged under this code show minimal direct procurement of ofloxacin specifically. Instead, the opportunities reflect broader pharmaceutical and medical supply sourcing—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals distributed through authorized wholesalers. The code's nominal scope (a single antibiotic agent) does not align with the actual buying activity, which centers on emergency response medications, pharmacy benefit management, and medical consumables rather than ofloxacin as a line item.

Recent opportunities span state health agencies, county health departments, city fire departments, and cooperative purchasing alliances. Seminole County, Florida solicited 1,900 units of naloxone annually via IFB 60459723LAS (due July 26, 2023); the City of Tampa issued ITB 26P00145 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, an estimated $700,000 contract designated for certified Small Local Business Enterprises with a 5 percent bid discount (due March 13, 2026); the Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across state and local facilities including Oregon (due March 26, 2026). The code shows activity in Florida, Texas, and Minnesota-led cooperative purchasing but limited evidence of direct ofloxacin procurement. Vendors evaluating this code should note the mismatch between the commodity name and actual buying patterns, which emphasize emergency response pharmaceuticals, multi-source generics through authorized wholesalers, and bundled medical supplies rather than single-agent antibiotics.